CIK 0001370053
- Non-accelerated filer
- Smaller reporting company
ANAPTYSBIO, INC
Sign in to watch- Ticker
- ANAB
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Jun 30
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 203828755
- Phone
- +1 858-362-6295
- Business address
- 10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA, 92121
- Former names
- ANAPTYSBIO INC, ANAPTYS BIOSCIENCES INC
- 4 Derivatives Options or other derivatives
- 4 Open-market sale President, CEO sold 36,645 shares at an average $35.57 ($1,303,559)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Grant or award Chief Medical Officer acquired 964 shares (grant or award)
- 4 Grant or award President, CEO acquired 964 shares (grant or award)
- 4 Grant or award COO, General Counsel acquired 523 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 964 shares (grant or award)
- 4 Open-market sale President, CEO sold 20,361 shares at $35.00 ($712,635)
- 4 Open-market sale COO, General Counsel sold 5,000 shares at $35.00 ($175,000)
- 4 Open-market sale President, CEO sold 36,646 shares at an average $32.31 ($1,184,106)
- 4 Open-market sale President, CEO sold 15,993 shares at $30.00 ($479,790)
- 4 Exercise or conversion President, CEO acquired 10,000 shares (option exercise)
- 4 Exercise or conversion President, CEO acquired 10,000 shares (option exercise)
- 4 Open-market buy Director bought 221,500 shares at an average $23.24 ($5,147,444)
- 4 Open-market buy Director bought 147,300 shares at an average $23.63 ($3,480,233)
- 3 Insider Initial Statement of Ownership
- 4 Open-market buy 10% owner bought 3,308,800 shares at an average $18.93 ($62,622,736)
- 4 Open-market buy 10% owner bought 29,500 shares at $25.48 ($751,657)
- 4 Derivatives Options or other derivatives
Page 9 of 15 · 298 filings